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Methods and patterns of use among
controls
R Bailie, J Katzenellenbogen, M Hoffman,
G Schierhout, H Truter, D Dent, A Gudgeon,
J van Zyl, L Rosenberg, S Shapiro
Objective. To describe the patterns of use of injectable
progestogen contraceptives (Ipes) among coloured and
black women in the Western Cape. These data are part of
an ongoing study in the Western Cape, the main aim of
which is to explore the relationship between IPes and
breast cancer.
Design. A population-based case-control study of breast
cancer risk in relation to the use of IPes among coloured
and black women.
Setting. The Western Cape, including the Cape
metropole and surrounding rural areas.
Study subjects. All coloured and black women with
newly diagnosed breast cancer, resident in the study area
and below age 55 years, who present at either of the two
tertiary care hospitals in the Western Cape are recruited.
Controls are a sample of hospitalised patients
representative of the populations from which the patients
are drawn. Cases are frequency-matched to controls
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according to cross-tabulation of age, ethnic group and
residential area in a ratio of approximately 1:3.
Measurements. Questionnaires are administered by
trained nurse interviewers. Information is elicited on a
wide range of variables, including sociodemographic
variables, medical history, family history of breast disease
lifetime history of all methods of contraception and use of
non-eontraceptive female steroids, reproductive variables
cigarette smoking, alcohol consumption and other
potentially confounding variables.
Results. Between January and December 1994, 122
incident cases and 389 controls were enrolled. Ever-use Ot
IPCs among the controls was 72% (N = 280) and use for 5
years or more was 30% (N ;:: 117). Use of IPCs in the
distant past was common, wrth 61 % (N = 232) of all
controls having initiated use 10 or more years previously.
Current use was also high (19%). Other contraceptive
methods were used far less commonly.
Conclusion. Coloured and black women in South Africa
have been using and continue to use IPCs far more
commonly and for longer periods than women anywhere
else in the world. It is therefore especially important to
evaluate the risk of breast cancer and other health effects
of IPCs. The rates of use identified in this study ensure
that there will be adequate statistical power to evaluate
long-term use, use in the distant past and current use of
IPCs.
S AfT Med J 1997; 87: 302-305.
Carcinoma of the breast [s a common cancer worldwide.!
Since hormonal contraceptives were introduced in the mid-
1960s there has been continued concern that they may
increase the risk of breast cancer. For oral contraceptives,
almost all of which are combinations of synthetic oestrogens
and progestogens, the relationship of use to breast cancer
risk has not been resolved, despite multiple rigorous and
large-scale studies.~ Recent evidence has raised the
possiblity that long-term use may be related to an increased
risk at young ages.~ Breast cancer risk in relation to
hormonal replacement therapy for post-menopausal women,
in the form of an unopposed oestrogen, or an oestrogen
together with a progestogen, has also been the subject of
much attention, again with uncertain results. 4
The influence of unopposed progestogen, principally
depot medroxyprogesterone acetate (DMPA). on the
development of breast cancer has received relatively scant
attention5 despite OMPA's being one of the most common
means of reversible birth control worldwide. The drug has
been widety used in both developing and some developed
countries, such as New Zealand.
'
Oral medroxyprogesterone
(Provera) is also increasingly being used as the progestogen
component of combined hormone (replacement) therapy.
South Africa offers a unique opportunity for investigation
of the association between exposure to IPes and the
development of breast cancer. There is an exceedingly high
level of long-term use and at the same time the presence, in
some regions, of technically advanced facilities for the
agnosis and treatment of breast cancer. In late 1993 a
.Jpulation-based case-control study was initiated, with the
1mary aim of assessing whether the long-term use (5 years
~ longer) of IPCs influences the incidence of breast cancer.
1is paper describes the methods and presents preliminary
ata on patterns of use.
'v1ethods
-he study region is a geographically defined area in the
Vestern Cape that lies within approximately 150 km of
~ape Town. The study population comprises all coloured
md black women resident in the study region, aged 19 - 54
ears - approximately 126 053 black women and 412 304
:oloured women. 7 This population is served by the two
najor tertiary care hospitals in the Western Cape, both
xated in Cape Town. Almost all women who develop
Jreast cancer are treated at these instiMions. Until recently
hese hospitals were the only institutions in the area that
Jffered specialised comprehensive treatment for breast
.ancer, including radiation therapy and chemotherapy.
All incident cases of invasive breast cancer diagnosed for
'le first time within the previous 6 months among coloured
md black women under the age of 55 years are identified at
he two tertiary care hospitals. The study is limited to
;oloured and black women because their level of IPC use
las been known to be partiCUlarly high, while use among
.vhite women has been low. The upper age limit of 54 years
s because IPCs (Initially DMPA and more recently
10rethisterone) came into common use in South Africa in the
llid-1960s; women older than 54 have had relatively little
.Jpportunity for exposure. Patients with carcinoma in situ are
excluded as are those with a previous history of malignancy
at any site. Cases are identified through regular contact with
the breast cancer clinics.
Controls, who are hospital patients without breast cancer,
are frequency-matched to cases by age (In 5-year age
categories). race and area of residence, with a case/control
ratio of approximately 1:3. Frequency matching is by
recruitment of controls according to cross-tabulation by all
three of these covariates. Additional criteria for recruitment
of controls are the following: (J) diagnoses must be
Independent of breast cancer risk; fil) the diagnosis resulting
in admission must be independent of contraceptive practice.
Both criteria require the exclusion of women admitted for
benign breast disease, and criterion 2 requires the exclusion
of women admitted for conditions such as myocardial
infarction or thrombo-embolism, since these conditions are
associated with the use of oral contraceptives. In addition,
women admitted for obstetric or gynaecological conditions,
rheumatoid arthritis, liver cancer and any long-standing
debilitating condition are also excluded because these
diseases may influence or be influenced by contraceptive
practice. Examples of suitable controls include admissions
for trauma, acute infections, orthopaedic conditions. acute
end other selected surgical condrtioos, and recently
diagnosed malignancies other than those of the female
genital tract or liver. Regular rotation through hospital wards
at the two tertiary hospitals is carried out in order to identrty
Controls. Interviewers spend 1 week in each ward
interviewing suitable controls from rural and urban areas
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who were admitted within the previous month. Additional
rural controls are recruited as required for matching to rural
cases of rotation through rural hospitals. Cases and controls
must have been resident in the study area for at least 6 of
the 12 months preceding diagnosis.
Most cases are interviewed within a week, and all within a
month of first presentation at the referral hospital. Cases are
interviewed etther when they attend a clinic or in the ward at
which they are treated as inpatients. Controls are
interviewed while they are inpatients. Pathological reports
are obtained to confirm the diagnosis for all cases and to
determine stage and tumour size. Discharge summaries are
reviewed to re-confirm the eligibility of the controls selected
by the nurse interviewers.
The interviews are conducted in the subject's home
language (Afrikaans, English or Xhosa) by nurses trained in
the administration of the questionnaires that were designed
and extensively tested in a pilot study. The accuracy of
translation of the questionnaire has been confirmed by
independent back-translation. To aid recall of contraceptive
use, the interviewers compile a calendar of significant
personal events (e.g. age at menarche, marriages, divorces,
births, miscarriages, sterilisation, age at menopause). and
relate periods of contraceptive use to those events. Samples
of oral hormonal medications are shown to SUbjects to
facilitate their identification. It is common practice in public
sector maternity units in the Western Cape routinely to
administer IPCs to women following delivery. Subjects are
therefore specifically asked whether or not they received
IPCs at these times and whether they were instructed to
report for a further contraceptive injection 2 or 3 months
later.
DMPA suppresses ovulation for several months when
administered by injection.The drug is readministered at 3-
monthly intervals and the total duration of exposure in
months can therefore readily be measured by mUltiplying the
number of injections by three. The use of injectable
norethisterone as an alternative has become more common
in the last decade. The total duration of use is similarly
defined, except that the interval between injections is 2
months and the muttiplication factor is therefore two.
In order to conduct a valid stUdy of breast cancer risk in
relation to contraceptive practice, information on a wide
range of other variables is being recorded in order to control
confounding and estimate possible effect modification.
These factors include age; ethnic group; religious affiliation;
history of benign breast disease; lifetime history of all
methods of contraception; use of non-contraceptive female
steroids; reproductive variables Qncluding age at first birth,
parity, gravidity, breast-feeding; miscarriages; elective
abortions; age at each pregnancy; age at menarche; and
age at menopause); weight; height; body shape; cigarette
smoking; alcohol co,sumption; family history of breast
cancer in a first-degree relative, and the age at occurrence
in that relative; years of education; employment status; and
occupation. Exposure to IPCs in the controls will be
examined in strata for each of the covariates, and in cases
and controls in order to identify possible confounding and
effect modification of each of these variables. With multiple
regression techniques, it wilt be possible to adjust for the
relevent covariates simuttaneously, and obtain adjusted
odds ratios for the effect of IPCs on breast cancer risk.
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Results
During the first year 122 cases (median age 43 years) and
389 controls (median age 42 years) were enrolled. The rates
of ever having used various contraceptives among the
controls were 73%. for IPes and 37% for OCs; 21 % of
women reported having been sterilised, 8% used IUDs, 2%
had used condoms and 2% of subjects reported that the
male partner had had a _vasectomy. Few women (less than
1%) reported using a diaphragm.
Rates of ever having used oral contraceptives are 22%
among black controls and 42% among coloured controls.
The corresponding figures for use for 5 years or more are
2% and 8%. Patterns of use of OGs will be reported on
when additional data have been collected. There were
sufficient data to analyse exposure to IPCs among controls
in some detail. The rate of ever having used Ipes for
coloured women and black women was 71 % and 77%
respectively. The corresponding figures for 5 years of use or
more are 27% and 44%. Table I gives the distribution of use
according to duration.
Table I. Duration of use of IPCs by diagnostic category
Group I Group 11 Group III All controls
No IPes 33 (23%) 43 (31 %) 33 (28%) 106 (27%)
< 1 year 27 (19%) 23 (16%) 15 (14%) 65 (17%)
1 - 4 years 41 (29%) 30 (21%) 31 (29%) 102 (26%)
5 - 9 years 19 (13%) 26 (19%) 20 (19%) 65 (17%)
10+ years 23 (16%) 18(13%) 10(9%) 51 (13%)
Total 143 140 109 389
Group 1~ infections and acute surgICal condltions; group 11 - elective surgical
condltioos, neoplasms, gasuo-intestlllal condinons; group III - trauma and
orthopaedic: concfrtions.
Rates of use for less than 1 year, 1 - 4 years,S - 9 years
and 10 years and more were 17%, 26%.17% and 13%.
respectively. Rates of use were similar in the three
diagnostic categories: 29%. 32% and 28% in each control
group were exposed to IPCs for 5 years or more.
Exposure to IPCs in the distant past was extremely
common; 20% of all controls had initiated use of IPCs 20 or
more years previously. Again. the distribution of distant
exposure was similar in the three diagnostic categories
(Table 11). Four per cent of controls reported initiating use of
IPCs within the previous 5 years.
Table 11. Time since first use of IPCs by diagnostic category
Group I Group 11 Group III All controls
Never used 33 (23%) 43 (31%) 30 (28%) 106 (27%)
< 1 year 1 (1%) 1 (1%) 2 (2%) 4 (1%)
1 - 4 years 5(4%) 4(3%) 4(4%) 13 (3%)
5 - 9 years 9(6%) 10 (7%) 8(8%) 27 (7%)
10· 14 years 24 (17%) 25 (18%) 18 (17%) 67 (17%)
15 - 19 years 34 (24%) 30 (21%) 28 (28%) 92 (24%)
20+ years 36 (25%) 27 (19%) 16 (15%) 79 (20%)
Total 142 140 106 388
same diagnostic groups as fOl" Table 1above.
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Current use of IPes or use within the previous year was
present in 19% of all controls. Distribution of the time
intervals since last use was similar in the diagnostic groups
(fable Ill).
Table Ill. Time since last use of IPCs by diagnostic category
Group I Group ]I Group III All contra
Never used 33 (23%) 43 (31%) 30 (28%) 106 (27%
Still using or 29(20%) 19 (14%) 25 (24%) 73 (19%
last used < 1
year previously
1 - 4 years 17 (12%) 19 (14%) 14(13%) 50 (13%
5 - 9 years 17 (12%) 21 (15%) 13 (12%) 51 (13%
10 -14 years 18 (13%) 18 (13%) 4(4%) 40 (10%)
15 - 19 years 17 (12%) 14 (10%) 16 (15%) 47 (12%
20+ years 11 (8%) 6(4%) 3 (3%) 20(5%)
Total 142 140 105 387
Diagnostic gIOUps as for Tables 1and I!.
Discussion
There is experimental evidence to suggest that unopposed
progestogens, and more specifically DMPA. may increase
breast cancer risk.8 This evidence is derived from
experiments on beagle dogs and many observers believe
that it is of no relevance to human risk.as Nevertheless, for
many years the findings in beagle dogs were sufficient to
persuade the United States Food and Drug Administration
(FOA) not to allow registration of OMPA for contraceptive
use. That policy was amended in 1992 when DMPA was
licensed for contraceptive use in the USA.'I) mainly as a
result of epidemiological findings in two studies of DMPA
and breast cancer in which no overall increase in the risk
was found. ''.12 A more detailed evaluation of the
epidemiological evidence reveals a more confusing picture,
since different studies have reported decreased risks. no
effect or increased risks associated wrth the use of
progestogen-only contraceptives. In a case-control study
confined to women below the age of 35 years, conducted in
the UK. the use of an oral progestogen was associated with
a significant duration-related reduction in the risk of breast
cancer. t3 Yet in a study carried out in Costa Rica.
'
• DMPA
use was associated with an increased risk. However. the UK
results are of limite:d generaJisability because breast cancer
that occurred after age 35 years was not studied and the
Costa Rican stUdy had high attrition rates that limited the
interpretability of the data.
Even the two studies that persuaded the FDA to license
DMPA were unclear inasmuch as increased risks were
identified in subgroups. In one of the studies an increased
risk of breast cancer before age 35 years was evident. but
not at more advanced ages.1I In the second study an
increased risk was evident for about 4 years after the
administration of DMPA but not therafter, in addition that
risk was only evident for short-term. but not for long-term,
use. 12 When the two studies were pooled the authors
reported: that the increased risk was a short-term one
confined to women who were currently using DMPA or who
had used it in the previous 5 years. However. it is
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Staff knowledge, attitudes
and practices in public
sector primary care of
diabetes in Cape Town
Objective, To audit staff knOWledge, attitudes and
practices in the interest of improved public sector primary
care for diabetics,
Design. External audit using face-ta-face, private,
questionnaire-based interviews.
Setting. Twelve public sector ambulatory health centres
in Cape Town.
Subjects_ Non-specialist, principal staff members
(N = 35) - 12 doctors, 10 primary health care nurses
(PHCNs), 7 registered nurses (RNs) and 6 staff nurses
(SNs).
Results. Staff members were long-standing employees
(mean - doctors 6 years, PHCNs 8 years, RNs 5 years,
SNs 12 years). Few had post-basic training (doctors 25%,
PHCNs 20%. RNs 26%, SNs 83%). Knowledge of chronic
diabetic complications was adequate, e.g. diabetic eye
disease was mentioned by 100% of staff. There were gaps
in knowledge of pathophysiology and of signs and
symptoms of diabetic emergencies, e,g. < 33% knew
control of hypertension to be important in the prevention
of diabetic nephropathy_ Knowledge of appropriate care of
patients with hypoglycaemia (94% mentioned glucose
administration) was better than that of hyperglycaemia
(69% mentioned intravenous fluids)_ Problems were
reported in inter·staff communication within
(approximately 50%) and between (approXimately 75%)
disciplines by doctors, PHCNs and RNs. Staff/patient
communication problems were reported by approXimately
75% of staff. Solutions suggested by staff included
meetings between staff members and with management,
in·service training programmes and appointment systems
for patients. Despite logistic, organisational and
communication-related problems, most staff enjoy and
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Jestionable whether pooling of these data is justifiable.
further problem with both studies is that there were
sufficient data to evaluate long-tenn use beyond S years,
- use in the distant past, e.g. during the teenage years
.vhen the developing breast may be uniquely susceptible).
There is therefore an urgent need for the re-evaluation of
reast cancer risk in relation to IPCs, and South African
,onditions offer a unique opportunity for further study. The
evels of exposure to lPCs identified in this study are higher
nan those previously reported, even in respect of exposures
nat took place a decade or more previously. In statistical
erms, this study will have sufficient power to document or
-ule out increased risks of the order of l_S-fold, even for 5 or
l10re years of exposure that took place as much as a
jecade previously. In addition, the study will have sufficient
JQwer to confirm or rule out the possibility that unopposed
;:Jrogestogens used for many years may decrease the risk of
oreast cancer, as has been suggested in one study. There is
excellent power to assess the hypothesis in respect of
current use, raised by two previous studies of DMPA and
breast cancer.'5
On the basis of the present findings it is already clear that
since the mid-1960s, the use of IPCs, mainly OMPA, has
oeen considerably more common in the South African
population than anywhere else in the world. Owing to these
high levels of use in South Africa, there is an important
public health need to determine whether or not these
methods of contraception are safe in tenns of cancer and
other health risks.
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